SMPX gene
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
CSL Behring to Close California R&D Site Amid Shift in Gene Therapy Strategy
CSL Behring, California R&D site closure, ex vivo gene therapy, strategic repositioning, biotech industry trends
CSL Behring Closes California R&D Site, Shifts Operations to Massachusetts Amid Strategic Repositioning
CSL Behring, California R&D site closure, gene therapy, ex vivo work, strategic repositioning, Massachusetts relocation